MyD88-IN-3

MyD88-IN-3 is an orally active, selective MyD88 inhibitor that specifically targets the TIR domain of MyD88 (KD= 28.5 μM) . It prevents MyD88 self-aggregation and its interaction with TLRs, thereby suppressing the activation of the MAPK and NF-κB pathways. MyD88-IN-3 exhibits significant anti-inflammatory effects and effectively alleviates symptoms of acute lung injury in CLP (cecal ligation and puncture) and LPS (lipopolysaccharide) -induced ALI models. This compound is valuable for ALI research.